Skip to main content
ONESOURCE · Health Care · 2026-08-28

Onesource Specialty Pharma Ltd

Stage 3 · wk 6In scan: Breakout WatchMARKET: WEAK RECOVERING · 2026-08-28
₹1,532.2
+0.97% today
₹17,570 Cr · Mid cap
About this companyHealth Care· Biotechnology
Expand ▾

OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India, Ireland, the United States, and internationally. The company provides end-to-end contract development and manufacturing operations (CDMO) services across various phases of preclinical and clinical development and commercial supply of biologics. It also offers drug-devices, including prefilled syringes, dial and push variable and fixed dose pen injectors, pull push fixed dose pens, and autoinjectors; sterile injectables; soft gelatin capsules; and biologics solutions for microbial and mammalian cell line biopharmaceuticals, cell and gene therapy, and RNA products. The company was formerly known as Stelis Biopharma Limited and changed its name to OneSource Specialty Pharma Limited in February 2024. OneSource Specialty Pharma Limited was incorporated in 2007 and is based in Bengaluru, India.

Visit company website →
vs 52W High
-19.3%
₹1,114 lo₹1,899 hi
19.3% below 52W high — weakening from peak
Stock is rolling over from its 52W high. Stage 3 distribution — new longs are high risk here.
Stage Maturity
Week 6
1w13w26w
Week 6 — distribution, avoid new longs
How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.
vs 200 DMA
-3.7%
200 DMA: ₹1,591.8 · sloping down
Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.
Rel Volume
0.13x
vs 50-day avg
Volume spikes on down days during Stage 3 signal distribution — institutions are exiting. A clear warning to avoid new longs.
Trend Health
MA20 rolling over · -4.7% vs MA50 -4.8%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↓ Peaking
Stage 2%
48.9%
20d Δ
-3.4pp
1M return
+3.0%
3M return
+13.6%
Sector Stage-2 % · last 20 days
Sector has 84 Stage 2 leaders. See Health Care Stage 2 →
Industry
Biotechnology
↓ Peaking
Stage 2%
44.4%
20d Δ
-27.0pp
1M return
+3.9%
3M return
+8.4%
Industry Stage-2 % · last 20 days
Industry has 4 Stage 2 leaders. See Biotechnology Stage 2 →
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2025-01-24 → 2026-08-28
S? 42w
S4 19w
2025-01-242026-08-28
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 42w → S3 4w → S4 19w → S1 6w → S2 7w → S3 6w current
Total tracked: 83 weeks across 6 stage runs.
1M
-9.2%
3M
-16.6%
6M
+15.7%
YTD
-11.5%
1Y
-16.8%
Scan Membership
Breakout Watch
Latest: 2026-06-05
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-28S3
Wk 6 · Vol x
2026-08-27S3
Wk 6 · Vol x
2026-08-26S3
Wk 6 · Vol x
2026-08-25S3
Wk 6 · Vol x
2026-08-24S3
Wk 5 · Vol x
2026-08-21S3
Wk 5 · Vol x
2026-08-20S3
Wk 5 · Vol x
2026-08-19S3
Wk 5 · Vol x
2026-08-18S3
Wk 5 · Vol x
2026-08-17S3
Wk 4 · Vol x
2026-08-14S3
Wk 4 · Vol x
2026-08-13S3
Wk 4 · Vol x
Sector Peers — Stage 2All →
MARKSANS
wk 15 · -1.0% from hi
9.8
BLISSGVS
wk 39 · 0.0% from hi
9.4
ENTERO
wk 3 · 0.0% from hi
9.2
GLAND
wk 14 · -2.8% from hi
8.8
ALBERTDAVD
wk 1 · 0.0% from hi
8.7
Moving averages & range
50 DMA
₹1,605.6
200 DMA
₹1,591.8
52W High
₹1,899
52W Low
₹1,114
5D Low
₹1,483.6
Resistance levels (recent highs)
20d High
₹1,598.9
60d High
₹1,789.7
120d High
₹1,867.4
250d High
₹1,899
Next resistance
+4.4%
to 20d High

All analytics based on EOD data. Data as of 2026-08-28. Past data patterns are not indicative of future results. This page is a data analytics tool only.